MX394213B - Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos. - Google Patents

Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos.

Info

Publication number
MX394213B
MX394213B MX2018001720A MX2018001720A MX394213B MX 394213 B MX394213 B MX 394213B MX 2018001720 A MX2018001720 A MX 2018001720A MX 2018001720 A MX2018001720 A MX 2018001720A MX 394213 B MX394213 B MX 394213B
Authority
MX
Mexico
Prior art keywords
critical care
use during
care treatment
parenteral formulation
during critical
Prior art date
Application number
MX2018001720A
Other languages
English (en)
Spanish (es)
Other versions
MX2018001720A (es
Inventor
Anna Kazanchyan
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/834,027 external-priority patent/US9399034B1/en
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Priority claimed from PCT/US2016/045094 external-priority patent/WO2017027249A1/en
Publication of MX2018001720A publication Critical patent/MX2018001720A/es
Publication of MX394213B publication Critical patent/MX394213B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2018001720A 2015-08-11 2016-08-02 Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos. MX394213B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562203731P 2015-08-11 2015-08-11
US201562203748P 2015-08-11 2015-08-11
US14/834,027 US9399034B1 (en) 2015-08-11 2015-08-24 Methods of sedation during critical care treatment
US15/185,650 US9717716B2 (en) 2015-08-11 2016-06-17 Methods of sedation during critical care treatment
PCT/US2016/045094 WO2017027249A1 (en) 2015-08-11 2016-08-02 Methods of sedation and parenteral formulation for use during critical care treatment

Publications (2)

Publication Number Publication Date
MX2018001720A MX2018001720A (es) 2018-09-06
MX394213B true MX394213B (es) 2025-03-24

Family

ID=59687449

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001720A MX394213B (es) 2015-08-11 2016-08-02 Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos.

Country Status (12)

Country Link
US (1) US20180235942A1 (enExample)
EP (1) EP3334427A4 (enExample)
JP (1) JP6857647B2 (enExample)
KR (1) KR20180048707A (enExample)
CN (1) CN108135889A (enExample)
AU (1) AU2016304737B2 (enExample)
CA (1) CA2994952A1 (enExample)
CO (1) CO2018002534A2 (enExample)
IL (1) IL257296B2 (enExample)
MX (1) MX394213B (enExample)
PE (1) PE20181332A1 (enExample)
TW (1) TWI763632B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108024997A (zh) 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
EP3833351A4 (en) 2018-09-20 2021-10-13 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS
KR20210110585A (ko) 2018-11-21 2021-09-08 썰테고 테라퓨틱스 아이엔씨. 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
MX2021007224A (es) 2018-12-17 2021-09-23 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
US20220218740A1 (en) * 2020-10-25 2022-07-14 Vaporworks Nursing Anesthesia Inc. Opioid-free compositions for anesthesiological applications and related methods and systems
CN117305294A (zh) * 2022-06-22 2023-12-29 苏州科锐迈德生物医药科技有限公司 一种环状rna的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071933A (en) * 1999-12-03 2000-06-06 Diversified Medical Innovations, Inc. Homogeneous remifentanil-propofol blend for patient controlled anesthesia and process for its use
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
ATE454140T1 (de) * 2004-02-18 2010-01-15 Sepracor Inc Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
US9399034B1 (en) * 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Also Published As

Publication number Publication date
KR20180048707A (ko) 2018-05-10
AU2016304737B2 (en) 2021-03-11
JP6857647B2 (ja) 2021-04-14
IL257296B2 (en) 2023-02-01
IL257296A (en) 2018-03-29
EP3334427A4 (en) 2019-02-06
AU2016304737A1 (en) 2018-02-22
TW201717944A (zh) 2017-06-01
EP3334427A1 (en) 2018-06-20
TWI763632B (zh) 2022-05-11
CN108135889A (zh) 2018-06-08
JP2018522920A (ja) 2018-08-16
CO2018002534A2 (es) 2018-05-31
CA2994952A1 (en) 2017-02-16
US20180235942A1 (en) 2018-08-23
IL257296B (en) 2022-10-01
MX2018001720A (es) 2018-09-06
PE20181332A1 (es) 2018-08-20

Similar Documents

Publication Publication Date Title
CY1124368T1 (el) Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
CO2018002534A2 (es) Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos
PH12017501046A1 (en) Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
MX378273B (es) Compuestos activos hacia bromodominios.
IL285440A (en) Oral compositions containing octreotide in combination with other therapeutic agents for tretment of acromegaly
NZ729252A (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
PL3381451T3 (pl) Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej
CL2015002897A1 (es) Inhibidores de bace1
HUE058151T2 (hu) Enterococcusból származó flagellin készítményei terápiában történõ alkalmazásra
MA50358A (fr) Sémaglutide en thérapie médicale
CY1122971T1 (el) Ενωσεις διυδροπυριμιδιν-2-ονης και ιaτρικη χρηση αυτων
CY1120573T1 (el) Παραγωγα πυριδαζινης για χρηση στην προληψη ή θεραπεια αταξικης διαταραχης
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2016014859A (es) Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas.
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
PT3215143T (pt) Combinação compreendendo espirulina e palmitoíletanolamida
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
IL258610B (en) Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer
IT201700124249U1 (it) Apparecchiatura portatile per la somministrazione di una miscela di gas nella rianimazione cardiopolmonare di un paziente
IL248428B (en) 3,1-propanedisulfonic acid or its pharmaceutically acceptable salt for use in the treatment of sarcoidosis
MX2018001575A (es) Compuestos triciclicos y su uso en el tratamiento del cancer.
AR095890A1 (es) Uso de ácido trifluoroacético y sales del mismo para tratar la hipercolesterolemia
UA100460U (uk) Застосування препарату ноофен як засобу лікування еректильної дисфункції в моно- або комплексній терапії